
Trump's Attempt At Reconfiguring Pharmaceutical Supply Chains And Its Effect On Transatlantic Relations
In the midst of attempts at rapid reshoring of manufacturing, U.S. President Donald Trump's proposed tariffs on pharmaceutical imports pose a significant threat to the cost of prescriptions for Americans, potentially increasing them by up to $51 billion annually. Transatlantic relations will be strained by the United States' plan to decrease its dependence on foreign medical products and redirect drug manufacturing to the United States.